Your cart is currently empty!
Category: Liver Cancer
Lenvatinib
Description
This page contains brief details about the drug lenvatinib, it’s indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.
Date of Approval
Lenvatinib is composed of the active ingredient Lenvatinib. It is a tyrosine kinase inhibitor indicated for progressive or advanced thyroid cancer when radioactive iodine therapy is not beneficial. It is also used to treat previously untreated liver cancer patients who are not eligible for surgical treatment. Patients who have had an allergic reaction to lenvatinib or any of its components should not take this medication. Patients should inform their dentist or oral surgeon that they are taking this medication, as it can impair wound healing and increase the risk of bleeding.
Lenvatinib was first approved by the United States Food and Drug Administration (FDA) in February 2015 for the treatment of locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer. Since then, it has received additional approvals for other indications, including the treatment of hepatocellular carcinoma (liver cancer) and renal cell carcinoma (kidney cancer).
Mechanism of Action of Lenvatinib
Lenvatinib blocks the enzyme receptor tyrosine kinases (RTKs). RTKs develop new blood vessels that supply oxygen and nutrients to the cells and help them grow. This medicine inhibits the receptors that facilitate the growth of blood vessels in tumor cells. RTKs are present in high concentrations in cancer cells, and administration of this medicine slows down the rate of cancer cells’ growth and multiplication.
Uses of Lenvatinib
Lenvatinib is a medication that is used to treat several types of cancer, including thyroid, liver, and kidney cancer. In patients with radioactive iodine-refractory differentiated thyroid cancer, it can be used to slow the progression of the disease and reduce tumor size. It is also approved for the treatment of unresectable hepatocellular carcinoma (HCC), which is the most common type of liver cancer.
Lenvatinib Dosage available
Lenvatinib is an oral medication that is usually taken once a day, at approximately the same time each day, with or without food. It should be taken as prescribed by a doctor or other healthcare provider. These capsules should be swallowed whole with a glass of water. They should not be crushed, chewed, or opened, as this can affect the way the medication is absorbed and decrease its effectiveness. You should not take a double dose to make up the second dose.
Cyclosporine
Description
This page contains brief details about the drug cyclosporine, it’s indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.
Date of Approval
Cyclosporine is an immunosuppressant which was approved for its medical use on 1983.
Mechanism of Action of Cyclosporine
Cyclosporine is an immunosuppressant which prevents organ rejection in organ transplantation. It is classified as an immunosuppressant belonging to the category of Calcineurin inhibitors. Cyclosporine works inhibiting cytochrome P450 3A4, P-glycoprotein and interleukins to suppress the cell mediated immune response. Cyclosporine is often prescribed along with other immunosuppressants like azathioprine and mycophenolate mofetil.
Uses of Cyclosporine
Cyclosporine has been developed to prevent organ rejection in adult and pediatric patients receiving an allogeneic transplant of the liver, kidney, heart, or lung. it is indicated for It is also prescribed to treat rheumatoid arthritis for patients who have not responded adequately to methotrexate.
Cyclosporine Dosage available
Cyclosporine is available in the form of capsule, injection and oral solution. Cyclosporine Capsule is available in the doses 25mg, 50mg and 100mg. Your healthcare provider will administer Cyclosporine 50mg Injection if you are unable to tolerate oral capsule or suspension. Your healthcare provider will prescribe the accurate dose based on the organ transplanted, body weight and health condition.
Tacrolimus
Description
This page contains brief details about the drug tacrolimus, it’s indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.
Date of Approval
Tacrolimus is an immunosuppressant that was approved for its medical use on 8th April 1994.
Mechanism of Action of Tacrolimus
Tacrolimus is an immunosuppressant that prevents organ rejection in organ transplantation. It is classified as an immunosuppressant belonging to the category of Calcineurin inhibitors. Tacrolimus works by binding to a protein called FKBP-12 and forms a complex called tacrolimus-FKBP, which inhibits the action of calcineurin phosphatase. This, in turn, inhibits the formation of T cells and suppresses the immune response. Tacrolimus is often prescribed along with other immunosuppressants like azathioprine and mycophenolate mofetil.
Uses of Tacrolimus
Tacrolimus has been developed to prevent organ rejection in adult and pediatric patients receiving an allogeneic transplant of the liver, kidney, heart, or lung.
Tacrolimus Dosage available Tacrolimus is available in the form of capsules, injections, oral suspensions, and ointments. Tacrolimus Capsule is available in doses 0.5mg, 1mg, and 5mg. your healthcare provider will administer Tacrolimus Injection (5mg/ml) if you are unable to tolerate an oral capsule or suspension. Your healthcare provider will prescribe the accurate dose based on the organ transplanted, body weight, and health condition. Patients diagnosed with cystic fibrosis might require higher doses.
Sorafenib Tosylate
Oncology
Sorafenat
Sorafenib was the first systemic therapy to be approved for the treatment of Liver cancer (Hepatocellular Carcinoma – HCC), but unfortunately the benefits could not reach patients as it was priced beyond the reach of most of the Indians. NATCO saw the plight of the suffering and responded by making the product available through compulsory license.
Today thousands of Liver and Kidney cancer patients are able to realise the benefits of Sorafenib through the efforts taken by NATCO to obtain compulsory license. Sorafenat has also helped to redefine the boundaries of Intellectual Property Rights in the context of life threatening diseases. Sorafenat is made available free to more than 600 poor and deserving patients every year.
Hepcinat and its combinations
NATCO living up to its purpose of “Making speciality medicines accessible to all” has launched generic brands of HEPCINAT (Sofosbuvir), HEPCINAT-LP (Ledipasvir/Sofosbuvir), NATDAC (Daclatasvir). NATCO is amongst the first companies to launch the generic versions of Sofusbuvir (SOF) and its combinations in India; this is truly a momentous occasion for the hepatitis C virus (HCV) care givers, patients and the company. With the affordable pricing of NATCO, therapy benefits would be accessible to all economic strata and even the semi-rural/rural areas of India. Eradication of HCV in India is a matter of time and is possible through concerted efforts and scaling up stringent preventive measures, screening, diagnosis & treatment.
SOF is a well-tolerated effective antiviral agent that is heralding a new era of all oral therapy for HCV. SOF is safe and can be used across different viral genotypes, disease stages, and special patient groups, such as those co-infected with human immunodeficiency virus. When used in combination with ribavirin or another direct-acting antiviral agent, SOF has revolutionized the HCV treatment spectrum and set the stage for nearly universal HCV antiviral therapy. More so than any other anti-HCV drug developed to date, SOF offers the widest applicability for all infected patients, and new regimens will be tailored to maximize performance. Sofosbuvir is truly an evolution and revolution in the treatment of HCV.
Ledipasvir+Sofosbuvir is a two-drug fixed-dose combination product that contains 90 mg of Ledipasvir and 400 mg of sofosbuvir in a single tablet, It is indicated for the treatment of chronic hepatitis C (CHC) genotype 1 infection in adults. Daclatasvir is the first-in-class NS5A inhibitor used in combination with Sofosbuvir for the treatment of patients with chronic HCV genotype 3 infection. Compared to other treatment options, this combination not only increases the cure rate, but is also regarded as a valuable treatment option in some of the difficult-to-treat HCV patient subsets.
HCV infection is the leading cause of advanced liver disease worldwide. The virus successfully evades host immune detection and for many years has hampered efforts to find a safe, uncomplicated, and reliable oral antiviral therapy. Initially, Interferon and Ribavirin therapy was the treatment standard of care, but it offered limited performance across the wide spectrum of HCV disease and was fraught with excessive and often limiting side effects.
HEPCINAT and its combinations are available throughout India and dispensed against the prescription of a Hepatologist/Gastroenterologist/HCV treatment specialist.